AELF FlightService Adds Fourth A330 to Fleet, Delivers COVID-19 Supplies in First Flight

AELF FlightService adds a fourth A330-200 to its fleet

AELF FlightService adds a fourth A330-200 to its fleet

CHICAGO, Oct. 06, 2021 (GLOBE NEWSWIRE) — AELF FlightService announced today that its fourth Airbus 330-200 (registered as 9H-JFS) is officially on the Maleth Aero certificate. In partnership with air charter specialist 26AVIATION, the aircraft commenced its first operational flight in auxiliary cargo configuration on Friday, Oct. 1, flying from Europe to Asia to deliver critical supplies to curb the global COVID-19 pandemic.

“With the rapid growth of e-commerce and constant need for transport of pandemic supplies, there is more than ever a need for innovative cargo solutions in the market,” said Joe Cirillo, Chief Operating Officer at AELF FlightService. “This additional aircraft allows us to expand our fleet to further meet that need.”

In 2020, together with European partners, AELF FlightService led the acquisition of the controlling interest in Malta-based airline Maleth Aero which has since added four A330s to its certificate, including this aircraft. With a total of eight widebody aircraft in full-time auxiliary cargo configuration, the airline has quickly become a leader in the fast-growing passenger to freighter (P2F) market.

“We are thrilled to add another widebody aircraft to our operation that will increase capacity and allow us to continue providing reliable, seamless and on-time service to our customers,” said Lee Jones, President of Maleth Aero.

AELF FlightService offers a full spectrum of services including single charter flights and mid-term ACMI/wet and damp leases, as well as more traditional liquidity solutions such as long-term operating leases, sale and leasebacks, sale and wet leasebacks, among other services.

For more information, visit AELF-FlightService.com.

Contact:
Natalie Matthews
nmatthews@aelf-flightservice.com
+1 312-319-4468

Related Images

Image 1: AELF FlightService adds a fourth A330-200 to its fleet

This content was issued through the press release distribution service at Newswire.com.

Attachment

VistaJet Hosts ‘The Surprise Reunion’

The Surprise Reunione

Touchdown on a VistaJet Global 7500

ASTONISHING JOURNEYS TO CELEBRATE TIME WITH FRIENDS AND FAMILY

Fully bespoke multi-generational adventures to reunite loved ones

London, October 6, 2021: Reunion noun. /ˌriːˈjuːniən/ — The act of people coming together after they have been apart for some time.

VistaJet, the first and only global business aviation company, today announced the launch of The Surprise Reunion, its latest creation in the Adventures in the Sky program for families. Designed in collaboration with world-renowned event planners Sharky & George, the thrilling adventures bring friends and families together from every corner of the globe. Whether on a little known sandy island in the Pacific Ocean or a stunning mountain with untouched snow as far as the eye can see, gatherings will be completely unique and original.

Prior to each journey, exciting and mysterious packages, including trip itineraries and challenge instructions, are delivered at each guest’s door. Perhaps an ancient map parchment, a set of engraved coins, or a cryptic message, each will be different from the next — and in some cases, delivered by unexpected characters. From there, VistaJet will ensure seamless travel by private jet from anywhere in the world, to the final destination.

With unparalleled experience flying into and out of the hardest to reach destinations and onboard service unlike any other, The Surprise Reunion flights are remarkable. As friends and family may be flying simultaneously on separate VistaJet aircraft, all in-flight activities and challenges will share a common theme to create an atmosphere of togetherness leading up to the reunion.

Matteo Atti, EVP of Marketing and Innovation at VistaJet said: “This past year has shown us that spending time with family and friends is what really matters. We assessed how to better serve our Members and imagined a reunion with loved ones of all ages, commencing at 45,000ft in the sky. In collaboration with our longstanding partner Sharky & George, we did just that by creating The Surprise Reunion.

Onboard fun

En route to reunite with family and friends

After more than a year of missed milestones and holiday gatherings, our hope is that this will give families and friends something exciting to look forward to, encouraging them to spend time together, exploring new places, creating new traditions, and celebrating every moment big and small.”

VistaJet’s Surprise Reunion can be completely tailored to meet passenger preferences and create the most imaginative experience. Inspiration itineraries include:

  • The Ultimate Quest: Imagine the world’s most elaborate treasure hunt that starts at home and culminates in all the family’s favorite people congregating on a private island surrounded by turquoise sea. Hidden maps and cryptic clues will be found along the way, interacting with characters who are not what they initially seem. Expect boat chases, drone delivery of intel, femmes fatales, buried chests, high-tech spy equipment, and a nail-biting narrative to inspire and excite all ages.
  • Adventure Race Across the Globe: Perfect for family and friends with a competitive streak. Teams are allocated one month before the VistaJet flights and are evenly split between ages, ability and geography. As soon as race packs are delivered, players will have time to collaborate on tactics and game plans. Upon arrival at the top of a mountain, in a beautiful chalet surrounded by pristine powder, the group receives a set of photos, video and physical challenges to kick off a week-long adventure, paramotoring over the peaks, tracking chamois, marmot or elk with a local biologist, and dog sledding to dinner.
  • Immersive Historical Experience: Travel back in time to Ancient Greece, where everyone will convene aboard a spectacular superyacht for two weeks in the Peloponnese to embark on a modern take on the 12 Labors of Hercules. Clues and challenges will be woven into the most unusual activities imaginable, from cave diving to capture Hydra from the bed of the sea, to recovering Golden Apples from the top of Mount Olympus in a climb to Greece’s highest peak.

For more information on VistaJet and its Adventures in the Sky offerings, please visit vistajet.com/children

– Ends –

Information
VistaJet | press@vistajet.com

About VistaJet 
VistaJet is the first and only global business aviation company. On its fleet of over 70 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.
VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.
More VistaJet information and news at vistajet.com

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet US Inc. is an Air Charter Broker that does not operate aircraft. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S. air carriers, including XOJET Aviation LLC.

Attachments

Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2)

Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2)

  • Covicept has initiated a Phase 2 multi-center, randomized, double-blind, placebo-controlled 150 patient clinical trial in Brazil
  • The study will evaluate safety and efficacy of PJS-539 in reducing viral load in patients with COVID-19
  • PJS-539 is a potent, once daily, oral pill that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses
  • Covicept is a California-based biotech company funded and operationally supported by Forbion, a leading European life sciences venture capital firm

San Diego, USA, October 6th, 2021 – Covicept Therapeutics, an antiviral drug development company, announced today that a double-blind, placebo-controlled Phase 2 trial of PSJ-539 has been initiated and has begun enrolling patients with mild-to-moderate COVID-19. PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential as a broad-spectrum antiviral drug targeting RNA viruses.

This multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate safety and efficacy of PJS-539 in patients recently diagnosed with COVID-19. The trial in up to 150 patients is being conducted in Brazil, led by Bruno M Tomazini, MD of the Hospital do Coração São Paulo. PSJ-539 is administered once a day over ten days and the primary endpoint of the study will be the effect of two different doses of PSJ-539 on viral load compared to placebo. Secondary endpoints include the frequency of hospitalization and need for mechanical ventilation. Results are anticipated by the end of the year (1). The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and anti-viral medications.

Covicept has discovered several new host-dependent mechanisms by which PSJ-539 inhibits viral infections underscoring its potential as a broad-spectrum antiviral drug targeting RNA viruses (2). In addition, PSJ-539 has strong anti-inflammatory and anti-fibrotic effects in preclinical models of SARS-CoV-2-induced pneumonia. PSJ-539 has previously been tested in human clinical trials, however its anti-viral potential is novel and Covicept holds an exclusive world-wide license to the new patents.

Large scale GMP manufacturing of PSJ-539 has been established.

Professor Tsimikas, Co-Founder, Chairman and Chief Executive Officer of Covicept, commented: “It is a significant milestone for this program to move into clinical development in less than a year since Covicept was founded. Our team, together with Forbion’s operational and financial support, provides the necessary synergy to bring this medicine to patients infected with SARS-CoV-2 as quickly as possible.”

Sander van Deventer, Covicept Board member and Operating Partner at Forbion, added: “Covicept is a great example of how academic researchers, entrepreneurs, and investors can join forces and in a very agile way bring new therapeutic options to patients. PSJ-539 has potential as a prophylactic and to treat early, moderate and severe disease to reduce viral load, to minimize transmission and infection, as well as to reduce the long-term effects. We are very excited by the progress the team has made in the past nine months and continue to support the company on its way to develop potential blockbuster anti-viral drugs.”

RNA viruses such as SARS-CoV-1 (“COVID”), SARS-CoV-2 (“SARS”), MERS-CoV (“MERS”), Dengue, Chikungunya, Zika and Ebola, are considered to be the most likely causes of devastating global pandemics. Vaccination strategies can prevent the spread of these viruses and protect individuals, but they require a significant lead time before implementation and demonstration of efficacy. Hence, a small molecule that can be stockpiled and used to inhibit viral replication would be an integral component of the response to pandemics caused by RNA viruses.

Details of the Covicept PSJ-539 program and results to date will be presented later today by Dr van Deventer at the Sachs 8th Annual Healthtech Investment Forum in Basel, Switzerland in the Spotlight Showcase at 12.20pm local time.

References

  1. Clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/show/NCT05008393?term=covicept&draw=2&rank=1
  2. Cell paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489987/

About Covicept Therapeutics, Inc.

Covicept Therapeutics, Inc. was founded in 2020 in San Diego, California USA, based on discoveries by Professor Sam Tsimikas, Professor Philip Gordts and Professor Jeffrey Eskowith. It is focused on the development of drugs to treat diseases caused by a variety of RNA viruses, including SARS-CoV-2. It is backed by $2.3 million in seed funding and operational support from leading European VC firm Forbion.

Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses. PSJ-539 has shown good tolerability and high potency with excellent and high biodistribution to tissues, including the lungs, in humans allowing for relatively low daily doses. PSJ-539 also inhibits fibrosis, a property that may be valuable for patients infected with SARS-CoV-2, both short term and long-term. The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and anti-viral medications.

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the
(bio-) pharmaceutical space. Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 70 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. For more information, please visit: www.forbion.com

Contacts

Covicept Therapeutics, Inc.
Professor Tsimikas, Co-Founder, Chairman and Chief Executive Officer
Tel: +1 (0) 858 699 3528
Sander van Deventer, Covicept Board director and Forbion Operating Partner
Tel: +31 (0) 6 5498 2592

Forbion
Laura Asbjornsen, Head of Communications
Email: laura.asbjornsen@forbion.com
Tel: +31 (0) 35 699 30 00

Consilium Strategic Communications
Ashley Tapp, Sue Charles, Kris Lam
Email: Covicept@consilium-comms.com
Tel: +44 (0)20 3709 5700

Ceridian to Deliver Dayforce Payroll Across Nine New Markets

TORONTO and MINNEAPOLIS, Oct. 05, 2021 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today announced plans to deliver Dayforce Payroll across nine new markets, including Germany, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand.

Today, organizations around the world use Dayforce Payroll to reduce global compliance complexities and enable real-time auditing of payroll data to pay their people accurately and on time. Dayforce Payroll bridges the gap between pay and time, removing the pressure and burden of the traditional payroll process.

“The Dayforce platform’s continuous calculation of pay and time within a single solution has redefined how global enterprises experience payroll,” said Joe Korngiebel, Chief Product and Technology Officer, Ceridian. “We’re excited to bring Dayforce Payroll to nine new markets to drive increased business value for our customers, while delivering superior user experiences for their people.”

With ever-changing compliance and regulatory requirements, multinational organizations can achieve a competitive advantage by adopting a modern payroll solution that helps minimize risk and protect the bottom line. Ceridian seamlessly facilitates global pay in over 160 countries allowing employers to navigate their international workforces through one consolidated system, including country-specific details down to the employee level.

“We look forward to helping our customers with operations in APJ and EMEA to better navigate the complexities of today’s business world by providing accurate, compliant, and always-on payroll solutions as part of our global HCM leadership,” concluded Korngiebel.

We anticipate that Dayforce Payroll will be available in these new markets beginning in 2022. To learn more about Dayforce Payroll, visit: Ceridian.com/Payroll

About Ceridian
Ceridian. Makes Work Life Better™.
Ceridian is a global human capital management software company. Dayforce, our flagship cloud HCM platform, provides human resources, payroll, benefits, workforce management, and talent management functionality. Our platform is used to optimize management of the entire employee lifecycle, including attracting, engaging, paying, deploying, and developing people. Ceridian has solutions for organizations of all sizes. Visit Ceridian.com or follow us @Ceridian.

Forward-Looking Statement

This press release contains forward-looking statements that involve a number of risks and uncertainties. Statements that are not historical facts, and our expectations, hopes, intentions or strategies regarding the future are forward-looking statements. Forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, management. Because such statements are based on expectations as to the future and are not statements of fact, actual results may differ materially from those projected. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release should be read in conjunction with the risks detailed in the “Cautionary Note Regarding Forward-Looking Information,” “Forward-Looking Statement”, “Risk Factors” and other sections of Ceridian’s Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and other filings with the Securities and Exchange Commission.

Media Contact:

Fahd Pasha
647.417.2136
Fahd.Pasha@Ceridian.com

Taiwan shares end down after early rebound

Shares in Taiwan closed lower Wednesday as investors took advantage of an earlier rebound, pocketing profits amid lingering concerns over possible volatility on the U.S. markets despite an overnight rally, dealers said.

With the benchmark 10-year U.S. Treasury yield on the rise, the local bellwether electronics sector largely came under pressure, while a spike in international crude oil prices lent support to large cap petrochemical stocks, preventing the broader market from falling further, they said.

The Taiex, the weighted index on the Taiwan Stock Exchange (TWSE), ended down 67.59 points, or 0.41 percent, at 16,393.16, after moving between 16,303.63 and 16,568.21 during the day. Turnover totaled NT$287.48 billion (US$10.29 billion).

The market opened up 0.17 percent and soon reached the day’s high as buying was triggered by the gains on the U.S. markets, with the Dow Jones Industrial Average having risen 0.92 percent and the tech-heavy Nasdaq index having increased 1.25 percent on Tuesday, dealers said.

The early gain failed to be sustained as selling emerged in the wake of losses incurred on other regional markets such as Tokyo and Hong Kong to push the Taiex down to negative territory, dealers added.

The fall continued into the end of the session, while market heavyweights, in particular contract chipmaker Taiwan Semiconductor Manufacturing Co. (TSMC), were the target of last-ditch buying which helped recoup part of their earlier losses and lent some support to the broader market, dealers added.

“I think the rally on the U.S. markets overnight was just technical in nature and more volatility could come if Capitol Hill fails to reach an agreement to raise the debt ceiling by Oct. 18 to prevent the government’s default on its debt,” Nan Hua Securities analyst Kevin Su said.

U.S. Treasury Secretary Janet Yellen has said she believes the economy would fall into a recession if the debt ceiling is not raised before a default on the U.S. debt.

“So, the Taipei market simply joined its counterparts in Tokyo and Hong Kong in giving up earlier gains as many investors here feared more negative leads will come from overseas,” Su said.

The bellwether electronics sector fell 0.51 percent after its earlier upturn was reversed as higher interest rates made them look less attractive, Su said.

“Fortunately, TSMC, the most heavily weighted stock in the local market, recovered part of its earlier losses or the tech sector and the entire Taiex would have fallen further,” Su said.

TSMC fell 0.17 percent to close at NT$571.00 after coming off a low of NT$565.00. Dealers said the stock saw strong technical support ahead of NT$569.00, the 240-day moving average.

Other tech large cap semiconductor stocks suffered more losses with United Microelectronics Corp., a smaller contract chipmaker, declining 1.96 percent to end at NT$59.90, and dynamic random access memory chip supplier Nanya Technology Corp. falling 4.95 percent to close at NT$61.40.

Also in the electronics sector, iPhone assembler Hon Hai Precision Industry Co., second to TSMC in terms of market capitalization, bucked the downturn by rising 1.48 percent to end at NT$103.00 after the contract electronics maker reported a 46.41 percent year-on-year increase in consolidated sales for September.

“The fourth quarter is a traditional peak season for Hon Hai so today’s buying also reflected this upbeat mood,” Su said.

Su said the petrochemical sector rose 1.49 percent, on the back of rising crude oil prices, adding, “the major entities under the Formosa Plastics Group’s corporate umbrella simply led the sector in going higher.”

Among them, Formosa Petrochemical Corp. increased 2.63 percent to close at NT$101.50, Formosa Plastics Corp. rose 2.61 percent to end at NT$118.00, Formosa Chemicals & Fibre Corp. increased 1.58 percent to close at NT$83.50, and Nan Ya Plastics Corp. ended up 1.24 percent at NT$90.00.

“But, higher crude prices cut both ways. Shipping and airline stocks in the transportation sector came under pressure amid fears over rising costs,” Su said.

The transportation sector fell 4.96 percent, with container cargo shipper Evergreen Marine Corp. falling 5.05 percent to close at NT$97.80, and Wan Hai Lines Ltd. declining 6.65 percent to end at NT$161.50. In addition, China Airlines fell 2.35 percent to close at NT$16.65 and EVA Airways dropped 2.67 percent to end at NT$18.20.

In the steel sector, which fell 1.67 percent, adding pressure to the main board, China Steel Corp., the largest steelmaker in Taiwan, declined 1.54 percent to close at NT$35.05, and Chung Hung Steel Corp. dropped 2.44 percent to end at NT$38.50.

“How the U.S. markets will perform is expected to continue to dictate the global financial markets,” Su said. “We have to watch closely not only whether the U.S. debt ceiling will be raised by the deadline but also the U.S. Treasury yield movement.”

According to the TWSE, foreign institutional investors sold a net NT$23.86 billion worth of shares on the main board Wednesday.

Source: Focus Taiwan News Channel

CORONAVIRUS/New COVID-19 case leads to Taipei elementary school class suspensions

A co-pilot at a Taiwanese airline was one of five imported COVID-19 cases confirmed Wednesday, leading to the suspension of classes at the two elementary schools attended by her children as a precautionary measure, according to the Central Epidemic Command Center (CECC) and Taipei City government’s Department of Health.

The co-pilot, a woman in her 40s, is fully vaccinated against COVID-19, having received a second dose of the Moderna vaccine in early August, CECC spokesperson Chuang Jen-hsiang (???) said at the daily COVID-19 press briefing.

She was on assignment to Anchorage, Alaska from Sept. 23-26, and quarantined for five days at the Novotel Taipei Taoyuan International Airport hotel on returning, where she tested negative for COVID-19 on Oct. 1.

The woman returned home on Oct. 2, flew to and from Singapore on Oct. 3, and spent Oct. 4 at home, Chuang said.

She tested positive for COVID-19 on Oct. 5. Although the test results indicate the infection is very recent, the CECC is unsure whether she contracted the disease in the United States or in Singapore, Chuang said.

Four of the co-pilot’s family members and two of her colleagues have tested negative for COVID-19, Chuang said.

Her two children are both students in Taipei, with one studying at Jian An Elementary School in the city’s Da’an District and the other at Wanfang Elementary School in Wenshan District.

Their classes have been suspended as a precaution, affecting 56 students in total, Zhang Hui-mei (???), who heads the disease control division of Taipei’s Department of Health, told reporters.

In Taiwan, flight crew are required to quarantine for fewer than the standard 14 days required for ordinary travelers.

Those who are fully vaccinated against COVID-19 have to quarantine for five days after returning to Taiwan from a long-haul flight, and then follow enhanced self-health management guidelines for nine days, during which they are not permitted to take public transportation or visit crowded areas.

They also have to be tested for COVID-19 on the fifth, ninth and 14th day after their return to Taiwan.

Vaccinated flight crew on short-haul flights, meanwhile, are required to follow self-health management guidelines for seven days, which involves a ban on group dining and large-scale gatherings.

They have to be tested for COVID-19 on the seventh and 14th day after returning to Taiwan.

Source: Focus Taiwan News Channel

CORONAVIRUS/More Pfizer-BioNTech vaccine doses to arrive this week: Terry Gou

Two shipments of the Pfizer-BioNTech (BNT) COVID-19 vaccine, totaling 1.6 million to 1.8 million doses, will arrive in Taiwan over the next two days, Hon Hai Precision Industry Co. founder Terry Gou (???) said Wednesday in a Facebook post.

The delivery will be part of 15 million doses of the Pfizer-BNT vaccine ordered by Hon Hai Precision Co./YongLin Charity, Taiwan Semiconductor Manufacturing Co., and the Buddhist Tzu Chi Foundation, which are all being donated to the government for distribution.

A total of 3.32 million doses of the BNT vaccine have been delivered to date, according to Central Epidemic Command Center (CECC) data.

CECC officials did not confirm the upcoming shipments at the daily COVID-19 press briefing on Wednesday. Typically, they only announce the delivery of vaccines once the shipment is en route to Taiwan.

As for the Moderna vaccine, Health and Welfare Minister Chen Shih-chung (???) said a shipment of that brand’s vaccines “will likely arrive in the next three days,” though he did not give details as to how many doses will be delivered.

In related news, the CECC announced Wednesday that it was adjusting when people can make appointments on the government’s 1922 platform to get a COVID-19 vaccine shot for the round of vaccinations from Oct. 15-21.

In this round, three groups of people will be eligible to receive their first shot of the Pfizer-BNT vaccine: individuals aged 12-22, people aged 47 and over, and those who suffer from serious or rare illnesses or injuries.

They will be able to make an appointment from 10 a.m. on Oct. 11 to 12 p.m. on Oct. 13.

Another two groups of people will be eligible for their second AstraZeneca vaccine jab in this round. These are people aged 18-55 who received their first shot on or before July 22, and individuals aged 56 and above who got their first shot on or before July 30.

Individuals in these groups will be able to make an appointment from 10 a.m. on Oct. 12 to 12 p.m. on Oct. 13.

By having different start times as to when appointments can be made, the process can be smoother, CECC spokesperson Chuang Jen-hsiang (???) said at a press briefing.

To date, nearly 13.57 million people, or 57.89 percent of Taiwan’s 23.45 million population, have received one shot of a COVID-19 vaccine, but only 14.6 percent, or 3.44 million people, have had the two doses needed to be fully vaccinated, according to data.

Source: Focus Taiwan News Channel

Taiwan military confirms ‘Yun Feng’ missile’s existence

Taiwan’s military has publicly confirmed for the first time the existence of the “Yun Feng” (Cloud Peak) medium-range surface-to-surface missile, which has been under development since the 1990s.

Defense Minister Chiu Kuo-cheng (???) mentioned the missile during a joint hearing of the Legislative Yuan’s Foreign Affairs and National Defense Committee and Finance Committee on a proposed special budget of NT$240 billion to boost Taiwan’s missile arsenal.

Asked about the development and capabilities of the Yun Feng missile by opposition KMT lawmaker Johnny Chiang (???), Chiu was unwilling to reveal any details, saying only that the military is still “working on it.”

It was the first time the Ministry of National Defense publicly acknowledged the existence of the missile, which is said to have a range of up to 1,500 kilometers.

The Yun Feng missile has reportedly been under development since the 1990s and is designed to strike land-based targets inside China, according to local and foreign media reports.

Capable of hitting strategic targets such as airports, harbors and command centers in inland China, the Yun Feng missile is a key part of Taiwan’s asymmetric warfare plan to erode China’s combat capabilities, said Su Tzu-Yun(???), a senior researcher at the Institute for National Defense and Security Research.

Su said the Chinese military’s biggest threat to Taiwan is its air force, and having the ability to attack China’s air bases and disrupt its planned sorties in a conflict would substantially boost Taiwan’s ability to defend itself.

Local media speculated last year that the Yun Feng missile was tested in April 2020, but the National Chung-Shan Institute of Science and Technology, Taiwan’s state-owned weapon systems development institution, refused to comment on the reports.

Though Chiang asked about the Yun Feng missile at the hearing, it is not covered under the proposed NT$240 billion special budget but rather under a secret military budget.

The NT$240 billion budget would go to the development and production of other missiles. About 64 percent would be allocated to anti-ship missiles, 18 percent to anti-air missiles and 18 percent to other types of missiles.

Source: Focus Taiwan News Channel